Namita Thapar's Emcure Pharmaceuticals IPO opens today: All you need to know
Emcure IPO: The price range of the IPO is ₹960-1,008 per share and investors can bid for 14 shares in one lot.
Updated on: Jul 3, 2024, 08:51:17 IST
The initial public offering (IPO) of Emcure Pharmaceuticals opens for subscription today (July 3). Ahead of the issue, the company's shares were trading at a premium of ₹265 in the unlisted market. Here are the top things you need to know about Emcure IPO before subscribing:

- The IPO includes fresh issue of equity shares worth ₹800 crore and an Offer For Sale (OFS) of 1.14 crore equity shares by promoters and existing shareholders.
- The price range of the IPO is ₹960-1,008 per share and investors can bid for 14 shares in one lot.
- At the upper end of the range, the company aims to raise ₹1,952 crore through the issue. Read more: Namita Thapar may gain ₹127 crore in Emcure Pharma IPO
- Investors reducing their stakes under the Offer For Sale (OFS) include Namita Thapar and Satish Mehta, as well as BC Investments IV Ltd.
- Shark Tank fame Namita Thapar will reportedly earn around ₹127 crore through the IPO.
- Namita Thapar will offload a partial stake of about 12.68 lakh shares under the OFS component.
- Net proceeds from the IPO will be utilised by the company for debt repayment and general corporate purposes. Read more: Watch| Shark Tank India's Namita Thapar on period problems: ‘Tough phase…’
- The company is headquartered in Pune and is involved in the development, manufacturing and global marketing of a diverse range of pharmaceutical products.
- In FY24, the company's revenue from operations grew 11% year-on-year (YoY) to ₹6,658 crore from ₹5,985 crore in the preceding financial year.
- Kotak Mahindra Capital Company, Jefferies India, Axis Capital and JPMorgan India are the book-running lead managers to the issue.

E-Paper


